A drug discovery platform
for genetic diseases
A drug
discovery
engine for
genetic
diseases

Rapidly produce novel drug & target combinations
that are effective for multiple indication

From personalized medicine for individuals to precision medicine for populations
QRGenetics develop a powerful AI-supported drug discovery engine
that utilizes exclusive spatial analytics and proprietary omics datasets,
to rapidly produce novel drug and target combinations
that are effective for multiple indication

From personalized medicine for individuals to precision medicine for populations QRGenetics develop a powerful AI-supported drug discovery engine
that utilizes exclusive spatial analytics and proprietary omics datasets,
to rapidly produce novel drug and target combinations
that are effective for multiple indication

Our Unique Discovery Process

Consolidate
Medical
data
Disease
data
Proprietary
database
Proprietary
Algorithms
Disease
Modeling
Protein
Modeling
Target
Identification
Drug
Discovery
Validate
Rapid clinical validation through preclinical tests, & in-human trials
Expand
Proprietary
Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders
Power
Create a vast library of validated drug + target combinations, ready for clinical trials

Our Discovery Edge

Expanding Indications

extend the impact of our treatments, benefiting a broader range of patients
Rapid Target & Drug Identification

Accelerating from years
to months
New Market Demand

for shelf products, developed drugs and patented drugs

From Rare Disease to Heart Failure

Rare Indication

2 years old
Was diagnosed with a rare genetic disease caused by a point mutation that impacted blood supply to multiple organs and affect growth and development

Matching treatment

FDA-approved drug was matched and tested in a pre-clinical trial
Based on the results, an IND was submitted and a multicentre clinical trial was initiated

Drug Indication
Expansion

Same drug was also found beneficial for
1,000,000
patients that suffers from heart failure

Pipeline

Drug
name
Indication
type
Indication
name
Pre-clinical trial
Results
Clinical partner research
Clinical trial

QR-100
Rare
Common
Neurodevelopmental disorder (NDPLH)
Autism Spectrum Disorder (ASD)
QR-755
Rare
Common
Common
Celiac Disease
Rheumatoid Arthritis (RA)
Inflammatory Bowel Disease (IBD)
QR-172
Rare
Common
Common
Common
Common
Common
Common
Common
Smooth Muscle Disease
Heart failure
Abdominal and aortic Aneurysm
Visceral myopathy
Deafness
Dystonia
Myopathy
Basal cell carcinoma

Management Team

Dr. Shane Wald Altman. Ph.D.

Co-Founder & CEO

Prof. Miguel Weil, Ph.D.

Co-Founder & Scientific advisor

Dan Lavi

Co-Founder, Entrepreneur
& Business Management

Dr. Noa Bielopolski, Ph.D.

Director of Science

Advisory Board

Ido Gonen

Board Member and
Business development
consultant

Dr. Dan Goldstaub

Board member
and Pharma consultant

Prof. Arnold Levine

Board Member and
Cancer research specialist

Prof. Hagit Baris Feldman

Genetic advisor

Contact us

A. Rokach Blvd 97, Tel Aviv-Yafo